Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL D30 versus HYDRO RESERP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL D30 versus HYDRO RESERP.
ALDORIL D30 vs HYDRO-RESERP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.
None Documented
None Documented
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
50-100 hours (terminal); prolonged in renal impairment, leading to accumulation on repeated dosing.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Renal: 30-40% as unchanged reserpine; biliary/fecal: 60-70% as metabolites.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination